Novozymes, a Danish company that provides enzymes for industrial and consumer use, and also manufactures recombinant biopharma products and APIs, will spend $35-$50 million to build a new facility at its existing site in Tianjin, China. The new factory will produce Bacillus-based Hyaluronic Acid (bHA), which is used in medical devices, topical eye care treatments and drug delivery. More details..

Stock Symbol: (NASDAQ OMX Copenhagen A/S (NZYM B))